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Abstract: Introduction: Alzheimer’s disease (AD) is the most common cause of dementia, character-
ized by a progressive decline in cognition and function. Current treatment options for AD include the 
cholinesterase inhibitors (ChEIs) donepezil, galantamine, and rivastigmine, as well as the N-methyl-D-
aspartate receptor antagonist memantine. Treatment guidelines recommend the use of ChEIs as the 
standard of care first-line therapy. Several randomized clinical studies have demonstrated the benefits of 
ChEIs on cognition, global function, behavior and activities of daily living. However, patients may fail 
to achieve sustained clinical benefits from ChEIs due to lack/loss of efficacy and/or safety, tolerability 
issues, and poor adherence to the treatment. The purpose of this review is to explore the strategies for 
continued successful treatment in patients with AD.  
Methods: Literature search was performed for articles published in PubMed and MEDLINE, using pre-
specified search terms. Articles were critically evaluated for inclusion based on their titles, abstracts, and 
full text of the publication.  
Results and Conclusion: The findings of this review indicate that dose up-titration and switching be-
tween ChEIs may help to improve response to ChEI treatment and also address issues such as lack/loss 
of efficacy or safety/tolerability in patients with AD. However, well-designed studies are needed to pro-
vide robust evidence. 
Keywords: Alzheimer’s disease, switching, AD treatment, cholinesterase inhibitors, dementia, adherence. 
1. INTRODUCTION 
Alzheimer’s disease (AD) is a neurodegenerative disor-
der that is often associated with aging [1]. AD is the most 
prevalent cause of dementia and is characterized by progres-
sive decline in cognition and global function, thereby affect-
ing activities of daily living (ADL) [2, 3]. 
Management of AD continues to remain a challenge for 
both patients and their caregivers given that the available 
pharmacological treatment options are only able to provide 
symptomatic relief. Tacrine, a potent cholinesterase inhibitor 
(ChEI), was the first drug approved for the treatment of AD. 
However, its use was discontinued due to a poor safety pro-
file, particularly hepatotoxicity [4]. Currently, the mainstay 
of treatment approved worldwide for AD includes ChEIs  
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(e.g. donepezil, galantamine, and rivastigmine) and an N-
methyl-D-aspartate receptor antagonist (memantine). In ad-
dition, many new symptomatic treatment options are under 
development [5]. 
Besides symptomatic treatments, many disease-
modifying therapies (DMTs) which aim to halt or reverse 
disease progression, are under extensive research. These 
DMTs aim to prevent Aβ aggregation, promote Aβ clear-
ance, or target Tau phosphorylation, which are considered 
the pathogenic mechanisms leading to neuronal death. To 
date, all Phase III studies evaluating the efficacy of the avail-
able DMTs have failed. It may be some time before the first 
DMT shows proven clinical efficacy and becomes available 
as an approved treatment. Until the emergence of new thera-
pies (including new symptomatic drugs), the mainstay for 
AD treatment is limited to the currently available drugs 
which may slow the progression of symptoms. Even after the 
emergence of DMTs, symptomatic therapies may still be a 
viable treatment option for patients with AD experiencing 
disease progression, therefore the argument could be made 
1875-5828/18 $58.00+.00 © 2018 Bentham Science Publishers 
Strategies for Continued Successful Treatment in Patients with Alzheimer’s Disease Current Alzheimer Research, 2018, Vol. 15, No. 10    965 
that it becomes imperative that these drugs must be used as 
optimally as possible to maximize the potential clinical out-
comes in patients with AD [6]. 
In this review, we discuss the available therapeutic op-
tions for symptomatic treatment of AD, focusing on dose up-
titration and switching among approved treatment options 
for optimal treatment outcomes. In addition, we have at-
tempted to discuss the rationale of within-class switching 
based on the pharmacokinetics (PK) and pharmacodynamics 
(PD) of drugs and patient-related factors.  
2. METHODS 
A literature search was performed for articles in the Eng-
lish language on AD, published in PubMed and MEDLINE, 
using the search terms “Alzheimer’s disease/Alzheimer’s 
dementia”, “cholinesterase inhibitors”, “donepezil”, “galan-
tamine”, “rivastigmine”, “switch”, “clinical”, “efficacy”, and 
“safety” (cut-off date: January 2017). All the studies re-
trieved from this search were critically evaluated for inclu-
sion based on their titles, abstracts, and full text of the publi-
cations. 
3. APPROVED TREATMENT OPTIONS FOR AD 
3.1. ChEIs 
Donepezil is indicated for the treatment of all stages of 
AD in the United States and Japan, and for mild-to-
moderately severe AD in Europe [7-10].  
Galantamine is indicated for the treatment of mild-to-
moderate dementia of the Alzheimer’s type in the US and 
Japan, and for mild-to-moderately severe dementia of the 
Alzheimer’s type in Europe [11-13].  
Rivastigmine is available as a transdermal patch and as 
an oral formulation [14-17]. Oral rivastigmine is approved in 
the US for the treatment of mild-to-moderate dementia of the 
Alzheimer’s type, and in Europe for mild-to-moderately se-
vere Alzheimer’s dementia [14, 16]. The rivastigmine patch 
is approved in the US across all stages of AD, in Europe for 
the treatment of mild-to-moderately severe AD, and in Japan 
for mild-to-moderate AD [15, 17-19].  
3.2. N-methyl-D-aspartate Receptor Antagonists (Me-
mantine) 
Memantine is approved for the treatment of moderate-to-
severe dementia of the Alzheimer’s type in the US, Europe 
and Japan [20-22].  
The approved treatment options for AD have been de-
scribed in detail in Table 1. 
4. INITIATION OF TREATMENT WITH ChEIs 
Guidelines by the European Federation of Neurological 
Societies (EFNS) and National Institute for Health and Ex-
cellence (NICE) recommend ChEIs as the standard of care 
for AD. They recommend treatment initiation at a lower 
dose, with gradual up-titration to higher approved doses for 
optimal treatment outcomes. Patients can be switched to 
other ChEIs based on the adverse event (AE) profile, adher- 
 
ence, possibility of drug interactions, and dosing profiles 
[23, 24]. Similarly, guidelines developed at the 4th Canadian 
Consensus Conference on the Diagnosis and Treatment of 
Dementia recommend treatment with ChEIs for patients with 
mild-to-severe AD (grade 1A) [25]. Moreover, guidelines in 
Japan recommend the use of ChEIs as the initial treatment 
for AD; switching is preferred among the ChEIs in case of 
intolerability and/or lack of efficacy [26]. 
5. DOSE UP-TITRATION 
To maximize the therapeutic benefit of treatment with 
ChEIs, there is growing scientific evidence that the treatment 
dose should be up-titrated and tailored to individual patients’ 
needs based on their disease stage and other clinical charac-
teristics [27]. ChEIs have been reported to show significant 
benefits on cognitive, global, functional, and behavioral out-
comes in a dose-dependent manner in clinical studies [27-
31]. 
The ACTION (ACTivities of daily living and cognitION 
in Patients with Severe Dementia of the Alzheimer’s Type) 
study (N=716) was a 24-week, randomized, double-blind 
study that compared the efficacy, safety, and tolerability of 
rivastigmine patches (13.3 mg/24h and 4.6 mg/24h) in pa-
tients with severe AD. The high-dose patch demonstrated 
significantly less decline in overall cognition (p<0.0001) and 
function (p=0.025) as compared with the 4.6 mg/24h patch 
[32]. In a 24-week, open-label extension of the ACTION 
study (N=397), there were no clinically relevant differences 
in safety and tolerability between patients who were up-
titrated from the 4.6 mg/24h rivastigmine patch to receive 
the 13.3 mg/24h patch, and patients who continued on the 
13.3 mg/24h patch. However, a greater decline was observed 
in patients with delayed up-titration to the high-dose 13.3 
mg/24h patch compared to patients who continued on the 
high-dose patch from the double-blind phase to the extension 
phase [33]. This indicates the importance of early and sus-
tained intervention with the high-dose patch to achieve 
maximum clinical benefit. In another 24-week, double-blind 
study, Japanese patients (N=859) were randomized to re-
ceive either the 4.6 mg/24h or 9.5 mg/24h rivastigmine patch 
or placebo. Patients receiving the 9.5 mg/24h patch reported 
delayed deterioration on the Japanese version of the Alz-
heimer’s Disease Assessment Scale-cognitive subscale 
(ADAS-J cog; p=0.005) and the Clinician’s Interview-Based 
Impression of Change plus Caregiver Input (CIBIC plus-J; 
p=0.067) [19]. Furthermore, in a global Phase III study con-
ducted in patients with moderate-to-severe AD (N=1467), 
patients receiving donepezil 23 mg/day showed significantly 
greater cognitive benefits, as assessed by the Severe Impair-
ment Battery (SIB) score, compared to patients who contin-
ued treatment with donepezil 10 mg/day (p<0.001) [28, 34]. 
Another study conducted in 61 Japanese patients reported no 
statistically significant difference in cognitive decline at any 
time after starting donepezil 10 mg/day [35]. These observa-
tions clearly highlight the dose-dependent efficacy of ChEIs. 
Therefore, it is suggested to maintain ChEI therapy on a 
higher dose, as long as it is tolerable, as it may provide a 
greater chance of slowing/delaying symptomatic disease 
progression [36]. 
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Table 1. Approved treatment options for Alzheimer’s disease.  
Compound Geographical area Approved indication Titration scheme Additional remarks (if any) 
US All stages of AD 5 mg/day for 4-6 weeks -->10 mg/day 
for at least 3 months--> 23 mg/day  
A 23 mg sustained-release tablet 
formulation is approved in the US 
for treatment of moderate-to-severe 
AD; administered once patients have 
been on a dose of 10 mg o.d. for at 
least 3 months.  
EU Mild-to-moderately severe 
AD 




Japan Mild-to-severe AD 3 mg/day for 1-2 weeks -->5 mg for at 
least 4 weeks--> 10 mg/day*  
*10 mg approved only for severe 
AD. 
US Mild-to-moderate AD 





Japan Mild-to-moderate AD 
4 mg b.i.d for 4 weeks-->8 mg b.i.d. 
over at least 4 weeks. 
Dose may be increased up to 12 mg 
b.i.d., if tolerated, after a minimum of 4 




US Oral: Mild-to-moderate AD 
Patch: All stages of AD  
EU Oral and patch: Mild-to-
moderately severe AD 
Oral: 1.5 mg b.i.d. --> 3 mg b.i.d. --> 
4.5 mg b.i.d.--> 6 mg b.i.d., if tolerated 
with a minimum of 2 weeks at each 
dose 
Patch: 4.6 mg/24h -->9.5 mg/24h --> 
13.3 mg/24h, if tolerated for a mini-
mum of 4 weeks at each dose*  
A target maintenance dose of 9.5 
mg/24h patch or 6 mg b.i.d. oral 
rivastigmine has been approved in 
most countries for the treatment of 
mild-to-moderate AD. 
*In the EU, patients may be 
switched to the 13.3 mg/24 h patch 
only after a minimum of 6 months of 





Japan Patch: Mild-to-moderate AD  4.5 mg --> increasing dose by 4.5 mg at 
4-week intervals up to the target size of 
18 mg.   
or 9 mg --> 18 mg after 4 weeks.  








Moderate-to-severe AD  5 mg o.d.--> 10 mg o.d.--> 15 mg o.d. -
-> 20 mg o.d. memantine, if tolerated 
for a minimum of 1-week at each dose 
In the US, memantine is available in 
extended release capsule form and is 
administered at an initial dose of 7 
mg o.d. and increased in 7-mg in-
crements to reach a maintenance 
dose of 28 mg o.d. with a minimum 
treatment period of 1 week at each 
dose level. 
a7-10; b11-13; c14-19, 32; d20-22. AD, Alzheimer’s disease; b.i.d., twice daily; o.d., once daily. 
6. SWITCHING BETWEEN ChEIs 
Although continuous dose optimization is an option for 
treating all stages of AD, certain patients may fail to achieve 
sustained clinical benefits from ChEIs, sometimes resulting 
in discontinuation of the treatment. In these patients, switch-
ing between ChEIs is a reasonable therapeutic option be-
cause it is crucial to not give up on treatment after the first 
therapy has failed owing to a lack of clinical benefit [37, 38]. 
In a multicenter, 2-year prospective study, the incidence of 
switching between ChEIs was 9.2 per 100 person-years 
among 611 patients treated at baseline [39]. 
The rationale for switching to alternative ChEIs is based 
on the lack of clinical response owing to inappropriate drug 
distribution and the complex molecular mechanisms in-
volved in the changes occurring in the brain. Moreover, dif-
ferences in individual pharmacological properties of ChEIs 
make switching between ChEIs an attractive option. Thus, 
patients who are not able to tolerate or benefit from one 
ChEI may tolerate or benefit from another [38]. Most pub-
lished studies have explored switching from donepezil to 
galantamine or rivastigmine. However, only a few studies 
have investigated the switch from galantamine to donepezil 
or rivastigmine and from rivastigmine to donepezil. In the 
subsequent sections of this article, we focus on the effects of 
switching from one ChEI to another owing to lack of effi-
cacy, tolerability, or adherence. Studies investigating switch-
ing have been summarized in Table 2. 
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Table 2. Studies showing switching options as a therapeutic strategy for Alzheimer’s disease. 
Reference Study Design Switch Type 
Total Number of 
Patients; Duration 
Results 




DPZ to oral RVG  382; 6 months 
Oral rivastigmine well-tolerated 
56.2% stabilized or improved on the CGIC 
48.9 % stabilized or improved on the MMSE 
57% stabilized or improved on the IADL scale 




DPZ/RIV to GAL 16; 6 months 
50% of patients reported stabilization/improvement in cognition, 
behavior and ADL after switch 




DPZ to GAL 105; 52 weeks 
Galantamine was generally well-tolerated; no change in cognitive 
performance with either a 4-day or 7-day washout period 
Bartorelli et al. 2005d 
Observational, 
prospective 
DPZ to RVG oral; 
GAL to RVG oral 
225, 3 months 66.7%-67.7% of patients stabilized or improved after the switch 
Sadowsky et al. 2005e Open-label DPZ to RIV 61; 28 days 
Rivastigmine was well tolerated after switching from donepezil 
without a wash out period 
Figiel et al. 2008f Open-label DPZ to RVG 270; 26 weeks 
69.7% patients showed improvement or no further decline in 
global functioning 
Grossberg et al. 2009g 
Randomized, 
controlled 
Oral RIV to RIV 
patch 
870; 28 weeks 
Switching to the rivastigmine patch was well tolerated; ≤2.5% 
reported nausea and ≤1.9% reported vomiting 





261, 5 weeks 
Both immediate and delayed switches were well-tolerated with 
similar rates of discontinuation 
Sadowsky et al. 2010i 
Open-label, 
prospective 
DPZ to RVG 
patch 
234, 25 weeks 
Both immediate and delayed switches were well tolerated. Cogni-
tive, behavioral and global outcomes were maintained in both 
groups 
Han HJ et al. 2011j 
Open-label, 
prospective 
Oral ChEIs to 
RVG patch 
164; 24 weeks 
82.8% and 64.3% of patients reported improvement or no decline 
on CGIC and the Korean version of MMSE scores, respectively 
Tian et al. 2013k 
Retrospective 
cohort study 
DPZ to RVG 
patch 
772, 12 months 
Adherence was slightly improved in patients who switched from 
oral donepezil to rivastigmine patch 
Sasaki and Horie 
2014l 
Outpatient DPZ to GAL 44; 3 months 
NPI scores improved significantly on BPSD 
Significant improvement in patients with moderate AD 




Oral ChEIs to 
RVG patch 
423; 6 months 
Switching from oral ChEI to the rivastigmine patch showed favor-
able effects as compared to those switching from the rivastigmine 
patch to oral ChEI 
Cagnin A et al. 2015n 
Observational, 
prospective 
Oral ChEIs to 
RVG patch 
174; 6 months 
56% of patients stabilized or increased the MMSE score as com-
pared to baseline 
a50; b48; c61; d40; e58; f43; g56; h41; i57; j46; k55; l47; m45; n44. AD, Alzheimer’s disease; ADL, activities of daily living; BPSD, behavioral and psychological 
symptoms of dementia; CGIC, clinical global impression of change; ChEIs, cholinesterase inhibitors; DPZ, donepezil; GAL, galantamine; IADL, Instrumental 
ADL; MEM, memantine; MMSE, mini-mental state examination; NPI, neuropsychiatric inventory; RVG, rivastigmine. 
 
6.1. Switching Owing to Lack of Efficacy 
Lack of efficacy is defined as significant deterioration 
despite the use of symptomatic medication at an effective 
dose for at least 6 months. In this case, switching can be per-
formed overnight with quicker titration until the minimal 
effective dose is reached [37].  
A prospective, multicenter, 3-month observational trial in 
patients with mild-to-moderately severe AD (N=225) was 
conducted to determine the response to switching from an-
other ChEI to rivastigmine when patients experienced dete-
rioration (loss of at least two Mini-Mental State Examination 
[MMSE] points in the past 6 months) with initial treatment. 
A total of 188 patients switched from donepezil to rivastig-
mine, 33 switched from galantamine to rivastigmine, and 
four switched from donepezil to galantamine. Overall, 67.7% 
and 66.7% of patients in the donepezil-rivastigmine and gal-
antamine-rivastigmine switch groups, respectively, re-
sponded to rivastigmine (Clinical Global Impression of 
Change [CGIC] score ≤4). Among the non-responders, 
>80% of patients had minimal worsening of the disease 
(CGIC score 5). MMSE scores also improved after switching 
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from both donepezil (p=0.008) and galantamine (p=0.05) to 
rivastigmine; however, this was observed when patients with 
an absolute change from baseline in MMSE score >5 were 
excluded [40].  
A 5-week core-phase of the prospective, parallel-group, 
open-label SWAP study (SWitch from Aricept to Patch) 
evaluated the effects of “immediate” (n=131) or “delayed” 
(n=130) switching from 5-10 mg/day donepezil tablets to the 
4.6 mg/24h rivastigmine transdermal patch following a 7-day 
withdrawal period [41]. This was followed by a 20-week 
extension phase with 9.5 mg/24h rivastigmine transdermal 
patch treatment [42]. Results from this study suggest that 
both switching strategies were well-tolerated. Global func-
tion remained stable during the course of the study and the 
mean change in CGIC scores was similar in both the imme-
diate and delayed switch groups (4.1; 95% confidence inter-
val [CI], 3.9-4.4 and 4.3; 95% CI, 4.1-4.4, respectively). At 
the end of the study, cognitive, behavioral, or global out-
comes were maintained in the switch groups with a modest 
decline in the Alzheimer's Disease Cooperative Study-
Activities of Daily Living Scale (ADCS-ADL) scores at 
Week 25 (-3.7; 95% CI, -4.9 to -2.4; p<0.0001). Most pa-
tients (55%) preferred the rivastigmine patch to the oral for-
mulation. Results from this study indicate that the majority 
of patients receiving donepezil may be switched safely to the 
rivastigmine patch without a withdrawal period [42]. In an-
other, 26-week open-label study (N=270), patients with 
mild-to-moderate AD not responding to donepezil were 
switched to receive rivastigmine 3-12 mg/day. Improve-
ment/stabilization of AD was reported in 69.7% of patients 
(136/195, observed case analysis) who did not respond to the 
treatment or declined while taking donepezil and were im-
mediately switched from donepezil to rivastigmine [43]. 
In a 6-month observational study conducted in 174 pa-
tients with AD who switched from oral ChEIs to the 9.5 
mg/24h rivastigmine patch, the MMSE score increased or 
stabilized in 56% of patients as compared to baseline. The 
main reasons for switching were lack/loss of efficacy with 
previous oral ChEIs (57%), tolerability concerns (33%), or 
both (10%) [44]. Another study (EVOLUTION, N=423) 
assessing the effectiveness of switching in patients with mild 
and moderate AD showed favorable effects of switching 
from oral ChEIs to the rivastigmine patch as compared to 
those switching from the rivastigmine patch to oral ChEIs. In 
this study, the reasons for switching therapy included loss of 
efficacy with previous ChEIs (41.4%), lack of response 
(28.8%), reduced tolerability (14.2%), and poor compliance 
to treatment (9.9%) [45]. A 24-week, prospective, open-
label, single-arm, multicenter study in patients with probable 
AD (N=164) was conducted to assess the effects of switch-
ing to the rivastigmine patch after a poor response from ini-
tial treatment with oral ChEIs (donepezil, galantamine or 
rivastigmine capsules). Poor response was defined as a de-
crease of at least two points on the Korean version of the 
MMSE (K-MMSE). At Week 24, 82.8% and 64.3% of pa-
tients reported an improvement or no decline on the CGIC 
and K-MMSE scores, respectively. Poor responders to oral 
ChEIs experienced improvement in symptom or disease sta-
bilization when switched to the rivastigmine patch [46]. 
The efficacy of galantamine in patients with mild cogni-
tive impairment/mild-to-moderate AD, who switched from 
donepezil to galantamine without a washout period or dose 
titration was elucidated in an outpatient study by Sasaki and 
Horie. Neuropsychiatric inventory scores improved signifi-
cantly on behavioral and psychological symptoms of demen-
tia, particularly in terms of delusions, agitation, and aberrant 
motor activity in patients with AD (p=0.027). Remarkable 
improvements were noted in patients with moderate AD 
(MMSE scores 10-19; p=0.007) while no improvement was 
noted in patients with mild cognitive impairment (MMSE 
scores ≥24; p=0.648) [47]. A retrospective chart review of 
16 patients with AD who had been on donepezil or rivastig-
mine and were switched to galantamine (4 mg/day, n=5; 8 
mg/day, n=7; 12 mg/day, n=4) reported stabiliza-
tion/improvement in cognition, behavior and ADL in 50% of 
patients even 6 months after switching treatment [48]. An-
other 52-week observational study evaluated the efficacy of 
galantamine on cognition in patients with mild-to-moderate 
AD, who were either naïve to ChEIs (naïve group, n=42) or 
failed to respond to donepezil and were switched to galan-
tamine (switch group, n=24). At the end of the study, no sig-
nificant difference between naïve and switch groups was 
observed on the Korean version of ADAS-cog (p=0.162). 
However, the results of the study suggest that, as the efficacy 
of galantamine on cognition was not inferior in the switch 
group than in the naïve group, switching between ChEIs may 
be a viable option for patients not responding to treatment 
[49]. 
6.2. Switching Owing to Lack of Safety and Tolerability  
In case of intolerance to initial therapy, it is recom-
mended to wait for complete resolution of side effects before 
switching to another treatment [37]. Efficacy and safety of 
switching from donepezil to oral rivastigmine in patients not 
responding or not tolerating donepezil was evaluated in a 
prospective study with AD patients (N=382). A total of 
74.4% and 54.5% of patients who were switched because of 
tolerability issues and lack of efficacy with donepezil (as 
assessed by CGIC), respectively, responded to rivastigmine. 
Discontinuation due to AEs with rivastigmine in patients 
who experienced tolerability problems or lack of efficacy 
with donepezil was 15.4% and 11.5%, respectively. Nausea 
(30.1%) and vomiting (14.1%) were the most common AEs 
reported during the study [50].  
ChEIs are associated with a range of side effects, includ-
ing gastrointestinal symptoms, particularly during the dose 
titration phase [51, 52]. It is believed that these side effects 
are related to high maximum concentration (Cmax) and a 
short time to Cmax (tmax) following oral administration, 
thereby leading to an increase in acetylcholine levels in the 
brain and periphery. Thus, strategies that lower Cmax and 
prolong tmax may be expected to improve the tolerability of 
ChEIs [51, 53]. The transdermal patch formulation may be 
beneficial for AD patients who are being switched from the 
initial treatment because of tolerability reasons. 
In a 6-month observational study (N=174) evaluating the 
effectiveness of switching from oral ChEIs to the rivastig-
mine patch, 56% of patients reported improvement or no 
further deterioration of the MMSE score compared to base-
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line. The main reasons for switching were lack/loss of effi-
cacy (57%), tolerability problems (33%) or both (10%). The 
most frequently reported AEs were skin reactions (16%) and 
gastrointestinal symptoms (7%); only 9% and 3% of patients 
discontinued because of these AEs, respectively [44], indi-
cating that the rivastigmine patch can be considered as a 
therapeutic strategy to improve treatment persistence [44, 
50]. This is consistent with the observation in the double-
blind randomized controlled trial determining efficacy and 
safety of the rivastigmine patch and capsule in which one-
third of gastrointestinal AEs were observed with the patch 
compared with the capsule [54].  
In the 5-week core phase of the SWAP study, patients 
were randomly assigned 1:1 to either an immediate switch or 
delayed switch group (7-day withdrawal period) from 5-10 
mg/day donepezil to the 4.6 mg/24h rivastigmine patch. Both 
an immediate or delayed switch from donepezil to rivastig-
mine was safe and well-tolerated in patients with mild-to-
moderate AD. Only 3.8% of patients from the immediate 
switch group and 0.8% from the delayed switch group who 
received the rivastigmine patch reported nausea. Further-
more, no discontinuations were reported due to nausea and 
vomiting. Results from this study indicated that most pa-
tients were able to switch directly to the rivastigmine patch 
without a washout period [41]. In addition, data from the 
extension-phase of the study revealed similar results. At least 
one AE (from application site reaction, agitation and fall) 
was reported in 70.5% (184/261) of the overall patient popu-
lation, with a greater number of patients from the immediate 
switch group (n=96 [73.3%]) in comparison with the delayed 
switch group (n=88 [67.7%]). Only ten (3.8%) and 11 
(4.2%) patients experienced both nausea and vomiting in the 
immediate and delayed switch groups, respectively [42]. 
Studies investigating the switch from donepezil to the ri-
vastigmine patch indicate that this transition has a good 
safety profile, is well tolerated and can be performed without 
a washout period [50, 55].  
The IDEAL (Investigation of TransDermal Exelon in 
ALzheimer’s disease) study was a 24-week randomized con-
trolled trial evaluating efficacy and safety of rivastigmine 
patches (9.5 mg/24h and 17.4 mg/24h) versus oral rivastig-
mine (3-6 mg b.i.d.) or placebo. All patients who completed 
the double-blind phase were eligible to enter the 28-week 
extension phase of the study. These patients (N=870) were 
switched directly to the 9.5 mg/24h patch, irrespective of 
their treatment during the double-blind phase, and up-titrated 
to the 17.4 mg/24h patch. During the first four weeks of the 
extension phase, the rivastigmine patch was well tolerated by 
patients previously randomized to rivastigmine; nausea and 
vomiting were reported in ≤2.5% and ≤1.9% of the patients, 
respectively [56]. The rivastigmine patch demonstrated good 
skin tolerability in both the IDEAL and SWAP studies [42, 
56]. 
A post-hoc analysis of data from three clinical trials [41, 
44, 58] conducted by Sadowsky CH et al. compared the tol-
erability of switching from donepezil to the rivastigmine 
patch (4.6 mg/24h) or rivastigmine capsules (3-12 mg/day). 
Results from this analysis indicate better tolerability of the 
rivastigmine patch versus rivastigmine capsules; there were 
fewer gastrointestinal AEs (nausea: 3.8% versus 32.9%; 
vomiting: 4.2% versus 24.1%, respectively) and discontinua-
tions due to AEs (14.6% versus 19.3%, respectively) with 
the patch [57]. Evidence from an open-label study suggests 
that switching patients from donepezil to rivastigmine with-
out a washout period is well tolerated [58]. In a more recent 
observational, retrospective, multicenter study conducted in 
patients with AD (N=1022), improved ease of administration 
(56.65%), tolerability (36.79%), efficacy (31.60%), and ad-
herence (18.59%) were the main reasons for switching to the 
rivastigmine patch from any oral ChEI [59]. Based on the 
literature review conducted by Sadowsky C, et al., it has 
been recommended that patients receiving a high dose of oral 
rivastigmine can be switched directly to the 9.5 mg/24h ri-
vastigmine patch, whereas those on the lower doses of oral 
rivastigmine should be switched to the 4.6 mg/24h patch and 
continue treatment for 4 weeks before up-titration to a high-
dose patch [60]. A double-blind study (N=105) conducted by 
Wilkinson et al. investigated the switch from donepezil to 
galantamine and explored the optimum length of a washout 
period, given the longer half-life of donepezil than galan-
tamine. Results from this study suggest that galantamine was 
generally well-tolerated; however, patients reported fewer 
gastrointestinal AEs if the washout period was 4 days rather 
than 7 days [61].  
To date, no published studies have assessed the clinical 
effects of switching patients from galantamine or rivastig-
mine to donepezil because of the lack/loss of efficacy or 
safety/tolerability issues [62]. From these reported clinical 
observations, it seems that within-class switch among ChEIs 
is valuable when the first prescribed ChEI is not tolerable or 
efficacious. Additionally, switching from oral ChEIs to the 
rivastigmine patch seems to be well-tolerated. 
7. FACTORS AFFECTING CLINICAL RESPONSE TO 
ChEIs 
In this section, we discuss differences in the pharmacoki-
netic and pharmacodynamic characteristics of ChEIs and 
how they may explain the benefit of within-class switching. 
These differences can be attributed to the diversity of the 
chemical structures, each of which belongs to an independ-
ent chemical class [63] (Fig. 1). Results from meta-analyses 
described in systematic review papers indicate that there is 
no difference amongst ChEIs in terms of cognition, ADL or 
global functions in patients with AD [64]. This may be true 
when considering collective treatment response in a patient 
population, but it may not be necessarily true in an individ-
ual patient as patients with AD have diverse characteristics 














Fig. (1). Chemical structures of cholinesterase inhibitors. 
7.1. Pharmacodynamics 
Donepezil and galantamine function as rapidly reversible 
selective inhibitors of acetylcholinesterase (AChE), whereas 
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rivastigmine is a slowly-reversible dual inhibitor of AChE 
and butyrylcholinesterase (BuChE) [65]. Galantamine, a 
relatively weak AChE inhibitor (half maximal inhibitory 
concentration [IC50] value of ~2.8-3.9 µM), appears to have 
similar clinical efficacy as that of donepezil (IC50: 15-24 nM) 
and rivastigmine (IC50: 4 nM) and this effect may be attrib-
uted to its allosteric potentiation ligand (APL) activity. It 
increases the probability of nicotinic acetylcholine receptor 
(nAChR) channel opening induced by nicotinic agonists and 
potentiates the agonist response of the nAChR subtypes [66]. 
The levels of nAChR subtypes are significantly reduced in 
patients with AD, compared with age-matched controls [67]. 
Rivastigmine exhibits a unique pharmacological property 
that enhances potency and selectivity in a different manner 
via dual AChE-BuChE inhibition. The potential clinical 
relevance of BuChE inhibition by rivastigmine in patients 
with AD has been demonstrated by the dynamic shift of cho-
linesterase activity. Following 12 months of treatment with 
3-12 mg/day rivastigmine in patients with mild AD, inhibi-
tion of AChE and BuChE activities in the cerebrospinal fluid 
was reported to be 45% and 58%, respectively [68]. In an-
other 13-week open-label study in patients with mild-to-
moderate AD, rivastigmine was associated with a decrease in 
AChE and BuChE activity by 42.6% and 45.6%, respec-
tively [69]. 
Donepezil is a highly specific AChE inhibitor, designed 
to exhibit very high selectivity for AChE [70]. Donepezil 
also shows high affinity for the sigma-1 receptor as well, 
which is believed to play a role in the pathophysiology of 
neuropsychiatric diseases, including AD [71]. Although it is 
not obvious if rivastigmine or galantamine show similar af-
finity for the sigma-1 receptor, the pleiotropic effect of 
donepezil may exhibit a unique pharmacological profile 
other than AChE inhibition. 
7.2. Pharmacokinetics 
Differences in route of administration (oral/ transdermal) 
or metabolism may influence the efficacy and safety of a 
drug. Orally administered drugs are absorbed through the 
gastrointestinal wall, and their plasma drug-concentration 
levels increase rapidly to the peak (Cmax). Drug plasma levels 
then drop and may reach their lowest level (Cmin) until the 
next dose is administered [72]. Larger and more frequent 
plasma level fluctuations may lead to an increased incidence 
of cholinergic side effects, including gastrointestinal AEs 
such as nausea and vomiting [73]. Thus, by reducing Cmax 
and slowing tmax, the occurrence of these AEs may be re-
duced and may help in achieving sustained efficacy [72, 73]. 
To achieve such a pharmacokinetic profile, a novel rivastig-
mine transdermal delivery system was developed. The patch 
shows a steady rivastigmine concentration-time profile as 
compared with the oral formulations. Systemic exposure 
(area under the concentration-time curve from zero to infin-
ity [AUC∞]) for the 9.5 mg/24h patch was approximately five 
times higher than that with the oral dose of 3 mg rivastig-
mine, whereas Cmax with the patch was 20% lower than that 
observed with the oral solution [53]. Rivastigmine is me-
tabolized to an inactive metabolite, NAP-226-90, by AChE 
and BuChE, with no involvement of the cytochrome P-450 
(CYP) system. Conversely, donepezil and galantamine are 
metabolized primarily by these enzymes [74]. This implies 
that rivastigmine has fewer clinically relevant drug-drug 
interactions, making it ideal for use in the elderly population 
being treated with multiple medications for numerous co-
morbidities [75]. 
7.3. Patient-Related Factors 
CYP2D6 is the key CYP-450 isoenzyme involved in the 
metabolism of donepezil and galantamine. The genetic 
polymorphism in CYP2D6 has been well investigated, and a 
large number of allelic variants are known, which may have 
been reported to be responsible for decreased, increased, or 
no enzyme activity. In a 6-month study, CYP2D6*10, a mu-
tant genotype, was found to be associated with a better re-
sponse to donepezil treatment in patients with AD. Moreo-
ver, the steady-state plasma concentration of donepezil in 
patients with mutant genotypes was higher than that in pa-
tients with the wild-type genotype [76]. Another study 
showed that patients with the single-nucleotide polymor-
phism (SNP) rs1080985 in the CYP2D6 gene had a rapid 
metabolism and hence a poor response to donepezil. This 
rapid metabolism is attributed to high enzymatic activity as a 
consequence of a higher gene expression associated with the 
G allele. Hence, the presence of this SNP may influence 
clinical response to donepezil in patients with AD [77]. 
There are no reports describing the effect of this particular 
SNP in the CYP2D6 gene on metabolism and/or efficacy of 
rivastigmine, as rivastigmine is not metabolized by the CYP-
450 isoenzymes [74].  
Differential effect of drugs in patients with AD may also 
be attributed to the SNPs of AChE. In a computational study 
conducted by Saravanaraman et al., results from molecular 
dynamics and docking study revealed that various non-
specific SNP forms of AChEs exhibit different dynamic 
properties, which in turn affects their ligand-binding proper-
ties. Of the reported 153 SNPs, four non-specific SNPs 
(A415G, P104A, V302E, and Y119H) that were predicted to 
be functionally unfavorable were found to be structurally 
stable. However, their conformational alterations were found 
to interfere with the binding of AChE inhibitors, suggesting 
it to be a reason for the differential effect of ChEIs in pa-
tients with AD [78]. Similar results were observed in another 
study conducted in patients with AD who underwent treat-
ment with AChE inhibitors (N=158). Of the 25 SNPs located 
in 3 cholinergic system genes (CHAT, CHT and ACHE), 
treatment response in patients with AD was found to have 
significant association with two SNPs of CHAT (rs2177370, 
rs3793790) [79]. Moreover, there are reports describing the 
difference in response in patients with specific SNP of mole-
cules related to the pleiotropic mode of actions of ChEIs. 
The pleiotropic APL effect of galantamine is explained by 
the allosteric activation of nAChR, by which galantamine 
potentiates ACh signals transmitted through the nAChR. The 
CHRNA7 gene is reported to encode α7 nAChR, one of the 
major nAChR subunits in the central nervous system (CNS), 
on chromosome 15q14. In a retrospective study conducted in 
233 patients with mild-to-moderate AD, the ratio of re-
sponders to non-responders with galantamine treatment was 
significantly higher in women with the SNP2 of CHRNA7 
rs8024987 compared with female non-carriers (p<0.01) [80]. 
A similar difference was not observed in patients treated 
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with other ChEIs, suggesting the involvement of the APL 
effect of galantamine through α7nAChR.  
Similar observations have been reported in patients carry-
ing a BuChE SNP and their clinical response to rivastigmine. 
Although many SNPs have been reported for the gene, the 
most prevalent non-synonymous substitutions SNP of Bu-
ChE is the K-variant (A539T). Carriers of this variant have 
been reported to have 33% lower enzyme activity in plasma. 
The allele frequency of the K-variant is reported to be 
around 10%, with some differences due to ethnicity [81]. In 
a post-hoc analysis of a study in 994 patients [82], BuChE 
wild-type carriers younger than 75 years showed signifi-
cantly greater treatment response to rivastigmine over 2 
years than patients receiving donepezil. However, BuChE K-
variant carriers experienced similar long-term treatment ef-
fects with both agents [83], suggesting that the greater effect 
of rivastigmine may be attributed to the inhibition of BuChE, 
which is fully expressed in the wild-type carriers. Further-
more, the efficacy of rivastigmine was also shown to be bet-
ter in patients carrying wild-type BuChE compared with 
those with the K-variant in an open-label study in 146 pa-
tients with AD. The difference was more evident in a 
subpopulation carrying allele ApoE4 [84]. 
These findings must be carefully interpreted considering 
the limitation of these analyses; some are retrospective 
analyses of studies with different study objectives and results 
being observed for a specific population (e.g. female subjects 
or patients younger than 75 years). Further elucidation in 
prospective studies with sufficient statistical power is re-
quired. Together with the polymorphism in the coding genes 
related to the cholinergic pathway, those present in the non-
cording region merits in-depth research as the non-coding 
microRNAs (CholinomiRs’) are believed to coordinate the 
cognitive and inflammatory aspects of cholinergic signaling 
by targeting major cholinergic transcripts including AChE 
[85]. 
In addition to the SNPs of molecules related to 
cholinergic pathway, some other patient conditions may also 
be implicated for the differential treatment response to 
ChEIs. BuChE expressed in the neuron and glial cells is re-
ported to be co-localized with senile plaques in AD brain and 
its enzyme activity positively correlates with the number of 
senile plaques in human autopsy brain samples [86, 87]. Mo-
lecular interactions of BuChE with amyloid beta protein 
(Aβ) and the role of BuChE in neuro-inflammation have also 
been reported [88-90]. The inhibitory potency of various 
ChEIs towards BuChE may also suggest the possibility of 
differential treatment response to ChEIs in patients with AD 
[91]. 
Apart from the intrinsic patient factors which may influ-
ence the treatment response to ChEIs, the potential impact of 
concomitant medications on cholinergic system cannot be 
ruled out. The negative effect of anti-cholinergic agents on 
cognition is widely reported [92, 93]. Combination of anti-
cholinergic drugs and ChEIs leads to pharmacological an-
tagonism which results in lack/loss of efficacy of ChEIs in 
patients with AD [94]. Hence, caution should be exercised 
during concurrent use of anti-cholinergic drugs and ChEIs. 
In summary, the main reasons for the potential difference 
in responsiveness to each ChEI can be attributed to the dif-
ferent chemical structure of the compounds and the diverse 
pathology of AD, which is not yet fully understood. Al-
though the individual responses to each ChEI vary due to 
their PK/PD properties and patient factors including genet-
ics, response of an individual patient to a particular com-
pound with the help of biomarkers is still not predictable. 
Responders and non-responders can be identified only after a 
treatment trial period with careful observation. In this con-
text, it is recommended to initiate therapy with any of the 
ChEIs, taking into account expected therapeutic benefits and 
potential safety issues [95]. Moreover, patients should be 
reviewed regularly using cognitive, global, functional and 
behavioral assessment(s), which may help physicians to de-
tect lack of efficacy of a treatment. 
8. SWITCHING AND PATIENT ADHERENCE 
Achieving maximal benefits from treatment is dependent 
upon patient adherence to the type of treatment used. A de-
cline in cognition, mood, and behavior can pose a challenge 
for patient adherence to a given medication [96]. Switching 
may positively affect treatment adherence through enhanced 
motivation of patients and caregivers by the expectation of 
the treatment option. A retrospective cohort study examined 
patient adherence using “proportion of days covered” (PDC) 
in 772 patients with AD who were new donepezil users and 
were subsequently switched to the rivastigmine patch [55]. 
Results from the analysis indicated that adherence improved 
in patients switching from oral donepezil to transdermal ri-
vastigmine. Patients who switched within the first year of 
initiating donepezil to rivastigmine patch exhibited increased 
adherence (PDC, 60.6% versus 69.3%; p=0.0004). Patients 
who switched from donepezil to the rivastigmine patch 
within the first 3 months (PDC, 80.4% versus 90.7%; 
p=0.04) exhibited even better adherence than those who 
switched between 7 and 9 months (PDC, 61.3% versus 
71.0%; p=0.05). Switching after 2 years did not result in 
increased patient adherence. Hence, the time to switch be-
tween the rivastigmine patch and donepezil tablets was a 
predictor of difference in PDC. This could be attributed to 
better tolerability with the transdermal patch, and/or per-
ceived convenience and ease of use of transdermal patches. 
It is suggested that an early decision to switch to another 
ChEI is beneficial for a patient’s outcome from the view-
point of treatment persistence [55]. Improvement of toler-
ability by switching may also contribute to improved effi-
cacy attributed by improved adherence and/or up titration to 
higher doses. Side effects of oral ChEIs, such as nausea and 
vomiting, are practical concerns while up-titrating to effica-
cious doses and may negatively affect drug adherence as 
well as motivation of patients and caregivers to stay on drug 
treatment. In a population-based cohort study using British 
Columbia claims data, approximately 50% of patients receiv-
ing ChEIs were reported to discontinue therapy within 12 
months of treatment initiation. A total of 3231/24,526 pa-
tients (new ChEI users) switched to a second ChEI within 90 
days of discontinuation of the first ChEI [97]. Similar results 
were reported in an Austrian cohort study (N=15,809) [98]. 
Considering the long disease course of AD, and the high rate  
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of treatment discontinuation in clinical practice, regular as-
sessment of disease progression and appropriate switching 
among ChEI may present a useful measure for better clinical 
outcomes by avoiding discontinuation of the treatment. 
CONCLUSION 
As donepezil, galantamine, rivastigmine, and memantine 
are the only available therapeutic options for the treatment of 
patients with AD, it is vital that clinicians optimize the use of 
available treatments until new preventive DMTs or sympto-
matic medications become available. Guidelines recommend 
ChEIs as the first choice of treatment, particularly for mild-
to-moderate AD. Based on the disease stage and clinical 
characteristics, the therapeutic dose should be up-titrated to 
the maximum approved dose, as long as it is tolerable, as it 
may help to improve response to ChEI treatment. Switching 
between ChEIs may also help to address issues such as 
lack/loss of efficacy or safety/tolerability in patients with 
AD. However, most of the switching studies referred to in 
this review are of an open-label design with potential bias, 
therefore well-designed studies are needed to provide robust 
evidence. In addition, future therapies will need to address 
multiple aspects of AD, for example, different pathogenic 
mechanisms and convergence of symptoms that may occur 
during the natural course of dementia. 
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